Cyclic adenosine 3',5' monophosphate in cerebrospinal fluid of multiple sclerosis patients.
Cyclic adenosine 3',5' monophosphate (cAMP) was assayed in CSF and plasma obtained from patients with multiple sclerosis. Decreased CSF cAMP levels were found in more than half of the patients while plasma cAMP was normal. The decrease is correlated significantly with the disability of the patient and with the progression of the disease. A low CSF cAMP level can be considered as prognostically unfavorable, particularly in the early stage of the disease. There was no correlation between the cAMP levels and the duration of the disease or with bouts and remissions. ACTH therapy did not normalize the decreased values. Obviously the decrease of CSF cAMP is related to the demyelination and not to the intensity of the pathological immunoreactions.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000242:Cyclic AMP / Q000134:cerebrospinal fluid*; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D011863:Radioimmunoassay; D012075:Remission, Spontaneous
D000324:Adrenocorticotropic Hormone; D000242:Cyclic AMP